Posted by Michael Wonder on 30 Oct 2023
Updated agenda for November 2023 PBAC meeting (30 October 2023)
30 October 2023 - The agenda for this week's November 2023 meeting has been updated.
There are four late changes:
- Tislelizumab (Tevimbra) - the submission has been withdrawn. A submission for tislelizumab will be considered at a future PBAC meeting.
- Imatinib mesylate, dasatinib monohydrate, nilotinib hydrochloride monohydrate, ponatinib hydrochloride, asciminib hydrochloride - the submission has been withdrawn. A submission for these tyrosine kinase inhibitors will be considered at a future PBAC meeting.
- Durvalumab (Imfinzi) - Review of positive PBAC recommendations not accepted by applicants. The review has been cancelled as AstraZeneca has advised the PBAC that a PBS listing of durvalumab is progressing.
- Essential amino acids with vitamins and minerals (EAA Supplement) - Review of positive PBAC recommendations not accepted by applicants. The review has been cancelled as Vitaflo has advised the PBAC that a PBS listing of essential amino acids formula with vitamins and minerals is progressing.
